| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = -$86,172 ) |
| | 2025 | 2023 | MOLECULAR TARGETING TECHNOLOGIES, INC. | 833 LINCOLN AVE | WEST CHESTER | PA | 19380-4471 | CHESTER | USA | R41HL167303 | Phosphatidylserine-blocking nanoparticles as improved anti-thrombotic with reduced bleeding risk | 000 | 1 | NIH | 5/1/2025 | $0 |
| | 2025 | 2022 | MOLECULAR TARGETING TECHNOLOGIES, INC. | 833 LINCOLN AVE | WEST CHESTER | PA | 19380-4471 | CHESTER | USA | R01CA226531 | Early Prediction of Tumor Response to Treatment: Clinical Translation of [99mTc]-Duramycin | 000 | 4 | NIH | 4/14/2025 | -$86,172 |
|
| Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2022 | MOLECULAR TARGETING TECHNOLOGIES, INC. | 833 LINCOLN AVE | WEST CHESTER | PA | 19380-4471 | CHESTER | USA | R01CA226531 | Early Prediction of Tumor Response to Treatment: Clinical Translation of [99mTc]-Duramycin | 000 | 4 | NIH | 12/29/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $1,299,322 ) |
| | 2023 | 2023 | MOLECULAR TARGETING TECHNOLOGIES, INC. | 833 LINCOLN AVE | WEST CHESTER | PA | 19380-4471 | CHESTER | USA | R41HL167303 | Phosphatidylserine-blocking nanoparticles as improved anti-thrombotic with reduced bleeding risk | 000 | 1 | NIH | 1/31/2023 | $299,890 |
| | 2023 | 2023 | MOLECULAR TARGETING TECHNOLOGIES, INC. | 833 LINCOLN AVE | WEST CHESTER | PA | 19380-4471 | CHESTER | USA | R44CA275434 | Instantaneous Tumor Spray for Real-Time Surgical Guidance | 000 | 2 | NIH | 7/31/2023 | $999,432 |
| | 2023 | 2023 | MOLECULAR TARGETING TECHNOLOGIES, INC. | 833 LINCOLN AVE | WEST CHESTER | PA | 19380-4471 | CHESTER | USA | R41HL167303 | Phosphatidylserine-blocking nanoparticles as improved anti-thrombotic with reduced bleeding risk | 001 | 1 | NIH | 6/21/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1,500,352 ) |
| | 2022 | 2022 | MOLECULAR TARGETING TECHNOLOGIES, INC. | 833 LINCOLN AVE UNIT 9 | WEST CHESTER | PA | 19380-4471 | CHESTER | USA | R44CA275434 | Instantaneous Tumor Spray for Real-Time Surgical Guidance | 000 | 1 | NIH | 8/10/2022 | $999,389 |
| | 2022 | 2022 | MOLECULAR TARGETING TECHNOLOGIES, INC. | 833 LINCOLN AVE UNIT 9 | WEST CHESTER | PA | 19380-4471 | CHESTER | USA | R01CA226531 | Early Prediction of Tumor Response to Treatment: Clinical Translation of [99mTc]-Duramycin | 001 | 4 | NIH | 4/29/2022 | $40,895 |
| | 2022 | 2022 | MOLECULAR TARGETING TECHNOLOGIES, INC. | 833 LINCOLN AVE UNIT 9 | WEST CHESTER | PA | 19380-4471 | CHESTER | USA | R01CA226531 | Early Prediction of Tumor Response to Treatment: Clinical Translation of [99mTc]-Duramycin | 000 | 4 | NIH | 1/12/2022 | $460,068 |
|
| Issue Date FY: 2021 ( Subtotal = $514,387 ) |
| | 2021 | 2021 | MOLECULAR TARGETING TECHNOLOGIES, INC. | 833 LINCOLN AVE UNIT 9 | WEST CHESTER | PA | 19380-4471 | CHESTER | USA | R01CA226531 | Early Prediction of Tumor Response to Treatment: Clinical Translation of [99mTc]-Duramycin | 002 | 3 | NIH | 4/23/2021 | $514,387 |
| | 2021 | 2020 | MOLECULAR TARGETING TECHNOLOGIES, INC. | 833 LINCOLN AVE UNIT 9 | WEST CHESTER | PA | 19380-4471 | CHESTER | USA | R01CA226531 | Early Prediction of Tumor Response to Treatment: Clinical Translation of [99mTc]-Duramycin | 001 | 2 | NIH | 1/11/2021 | $0 |
| | 2021 | 2019 | MOLECULAR TARGETING TECHNOLOGIES, INC. | 833 LINCOLN AVE UNIT 9 | WEST CHESTER | PA | 19380-4471 | CHESTER | USA | R01CA226531 | Early Prediction of Tumor Response to Treatment: Clinical Translation of [99mTc]-Duramycin | 000 | 1 | NIH | 12/30/2020 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $570,747 ) |
| | 2020 | 2020 | MOLECULAR TARGETING TECHNOLOGIES, INC. | 833 LINCOLN AVE UNIT 9 | WEST CHESTER | PA | 19380-4471 | CHESTER | USA | R01CA226531 | Early Prediction of Tumor Response to Treatment: Clinical Translation of [99mTc]-Duramycin | 000 | 2 | NIH | 2/3/2020 | $570,747 |
| | 2020 | 2018 | MOLECULAR TARGETING TECHNOLOGIES, INC. | 833 LINCOLN AVE UNIT 9 | WEST CHESTER | PA | 19380-4471 | CHESTER | USA | R43CA224579 | Sprayable, Prompt Color Changing Dye to Delineate Ovarian Cancer During Surgery | 000 | 1 | NIH | 9/28/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $608,921 ) |
| | 2019 | 2019 | MOLECULAR TARGETING TECHNOLOGIES, INC. | 833 LINCOLN AVE UNIT 9 | WEST CHESTER | PA | 19380-4471 | CHESTER | USA | R01CA226531 | Early Prediction of Tumor Response to Treatment: Clinical Translation of [99mTc]-Duramycin | 000 | 1 | NIH | 1/30/2019 | $585,113 |
| | 2019 | 2019 | MOLECULAR TARGETING TECHNOLOGIES, INC. | 833 LINCOLN AVE UNIT 9 | WEST CHESTER | PA | 19380-4471 | CHESTER | USA | R43CA224579 | Sprayable, Prompt Color Changing Dye to Delineate Ovarian Cancer During Surgery | 000 | 1 | NIH | 2/8/2019 | $23,808 |
| | 2019 | 2017 | MOLECULAR TARGETING TECHNOLOGIES, INC. | 833 LINCOLN AVE UNIT 9 | WEST CHESTER | PA | 19380-4471 | CHESTER | USA | R43AI133620 | Topical Drug Treatment of Cutaneous Leishmaniasis | 000 | 1 | NIH | 9/10/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $229,603 ) |
| | 2018 | 2018 | MOLECULAR TARGETING TECHNOLOGIES, INC. | 833 LINCOLN AVE UNIT 9 | WEST CHESTER | PA | 19380-4471 | CHESTER | USA | R43CA224579 | Sprayable, Prompt Color Changing Dye to Delineate Ovarian Cancer During Surgery | 000 | 1 | NIH | 4/9/2018 | $229,603 |
|
| Issue Date FY: 2017 ( Subtotal = $214,174 ) |
| | 2017 | 2017 | MOLECULAR TARGETING TECHNOLOGIES, INC. | 833 LINCOLN AVE UNIT 9 | WEST CHESTER | PA | 19380-4471 | CHESTER | USA | R43AI133620 | Topical Drug Treatment of Cutaneous Leishmaniasis | 000 | 1 | NIH | 7/14/2017 | $214,174 |
| | 2017 | 2015 | MOLECULAR TARGETING TECHNOLOGIES, INC. | 833 LINCOLN AVE UNIT 9 | WEST CHESTER | PA | 19380-4471 | CHESTER | USA | R43HL127892 | A PE-specific SPECT probe for the early detection of cancer treatment-induced cardiotoxicity. | 000 | 1 | NIH | 11/8/2016 | $0 |
| | 2017 | 2014 | MOLECULAR TARGETING TECHNOLOGIES, INC. | 833 LINCOLN AVE UNIT 9 | WEST CHESTER | PA | 19380-4471 | CHESTER | USA | R42AI073064 | A novel vaccine: botulinum neurotoxin subunit on a viral carrier. | 000 | 5 | NIH | 11/4/2016 | $0 |
|
| Issue Date FY: 2015 ( Subtotal = $224,819 ) |
| | 2015 | 2015 | MOLECULAR TARGETING TECHNOLOGIES INC | 833 LINCOLN AVE UNIT 9 | WEST CHESTER | PA | 19380-4435 | CHESTER | USA | R43HL127892 | A PE-specific SPECT probe for the early detection of cancer treatment-induced cardiotoxicity. | 000 | 1 | NIH | 3/23/2015 | $224,819 |
|
| Issue Date FY: 2014 ( Subtotal = $833,079 ) |
| | 2014 | 2014 | MOLECULAR TARGETING TECHNOLOGIES INC | 833 LINCOLN AVE UNIT 9 | WEST CHESTER | PA | 19380-4435 | CHESTER | USA | R42AI073064 | A novel vaccine: botulinum neurotoxin subunit on a viral carrier. | 000 | 5 | NIH | 5/21/2014 | $833,079 |
| | 2014 | 2012 | MOLECULAR TARGETING TECHNOLOGIES INC | 833 LINCOLN AVE UNIT 9 | WEST CHESTER | PA | 19380 | CHESTER | USA | R42AI081334 | Human Rabies Virus Vaccine Development | 000 | 3 | NIH | 8/14/2014 | $0 |
|
| Issue Date FY: 2013 ( Subtotal = $1,078,417 ) |
| | 2013 | 2013 | MOLECULAR TARGETING TECHNOLOGIES INC | 833 LINCOLN AVE UNIT 9 | WEST CHESTER | PA | 19380-4435 | CHESTER | USA | R43GM108470 | MULTICOLOR CELL MEMBRANE PROFILING FOR DEVELOPMENT AND DISEASE | 000 | 1 | NIH | 8/5/2013 | $219,935 |
| | 2013 | 2013 | MOLECULAR TARGETING TECHNOLOGIES INC | 833 LINCOLN AVE UNIT 9 | WEST CHESTER | PA | 19380-4435 | CHESTER | USA | R42AI073064 | A novel vaccine: botulinum neurotoxin subunit on a viral carrier. | 000 | 4 | NIH | 5/14/2013 | $858,482 |
|
| Issue Date FY: 2012 ( Subtotal = $1,457,619 ) |
| | 2012 | 2012 | MOLECULAR TARGETING TECHNOLOGIES INC | 833 LINCOLN AVE UNIT 9 | WEST CHESTER | PA | 19380-4435 | CHESTER | USA | R42AI073064 | A novel vaccine: botulinum neurotoxin subunit on a viral carrier. | 000 | 3 | NIH | 6/21/2012 | $817,599 |
| | 2012 | 2012 | MOLECULAR TARGETING TECHNOLOGIES INC | 833 LINCOLN AVE UNIT 9 | WEST CHESTER | PA | 19380-4435 | CHESTER | USA | R43AI094709 | ANIONIC PHOSPHOLIPID-SELECTIVE PET/SPECT AGENT FOR INFECTION IMAGING | 000 | 1 | NIH | 6/15/2012 | $224,438 |
| | 2012 | 2012 | MOLECULAR TARGETING TECHNOLOGIES INC | 833 LINCOLN AVE UNIT 9 | WEST CHESTER | PA | 19380-4435 | CHESTER | USA | R42AI081334 | Human Rabies Virus Vaccine Development | 000 | 3 | NIH | 7/12/2012 | $415,582 |
|
| Issue Date FY: 2011 ( Subtotal = $414,018 ) |
| | 2011 | 2011 | MOLECULAR TARGETING TECHNOLOGIES INC | 833 LINCOLN AVE UNIT 9 | WEST CHESTER | PA | 19380-4435 | CHESTER | USA | R42AI081334 | Human Rabies Virus Vaccine Development | 000 | 2 | NIH | 8/9/2011 | $414,018 |
|
| Issue Date FY: 2010 ( Subtotal = $572,812 ) (Continued on the next page) |
| | 2010 | 2010 | MOLECULAR TARGETING TECHNOLOGIES INC | 833 LINCOLN AVE UNIT 9 | WEST CHESTER | PA | 19380-4435 | CHESTER | USA | R44CA136306 | RADIOHYBRIDIZATION IMAGING OF HER2 ONCOGENE TO DETECT BREAST CANCER | 000 | 3 | NIH | 8/18/2010 | $350,159 |
| | 2010 | 2010 | MOLECULAR TARGETING TECHNOLOGIES INC | 833 LINCOLN AVE UNIT 9 | WEST CHESTER | PA | 19380-4435 | CHESTER | USA | R44CA136306 | RADIOHYBRIDIZATION IMAGING OF HER2 ONCOGENE TO DETECT BREAST CANCER | 001 | 3 | NIH | 9/23/2010 | $26,429 |
| | 2010 | 2010 | MOLECULAR TARGETING TECHNOLOGIES INC | 833 LINCOLN AVE UNIT 9 | WEST CHESTER | PA | 19380-4435 | CHESTER | USA | R43GM093417 | DUAL MODALITY LABELS FOR MACRO AND MICRO DETECTION AND QUANTIFICATION OF STEM CEL | 000 | 1 | NIH | 7/12/2010 | $196,224 |
| | 2010 | 2009 | MOLECULAR TARGETING TECHNOLOGIES INC | 833 LINCOLN AVE UNIT 9 | WEST CHESTER | PA | 19380 | CHESTER | USA | R43EB009591 | BRIGHT AND STABLE NEAR-IR DYES FOR BIOIMAGING | 000 | 1 | NIH | 8/10/2010 | $0 |
| | 2010 | 2009 | MOLECULAR TARGETING TECHNOLOGIES INC | 833 LINCOLN AVE UNIT 9 | WEST CHESTER | PA | 19380 | CHESTER | USA | R43EB009266 | SUPERIOR NEAR-IR DYES FOR BIOIMAGING | 000 | 1 | NIH | 6/17/2010 | $0 |
|
